Novartis is moving fast into mRNA-based autoimmune treatments. On October 2, 2026, the company locked in a licensing and option deal with China's Abogen Biosciences. The agreement could reach $7.8 billion. Novartis now holds exclusive global rights to ABO2203, plus options on more RNA programs. Both companies confirmed the deal. Details appeared in a Reuters financial review.
Novartis will pay $575 million upfront for ABO2203. If Novartis takes up further options and meets targets, Abogen could get another $7.2 billion in milestone payments. Abogen will also receive royalties on future sales. The deal still needs regulatory approval and must clear standard closing steps. An official company press release confirms Novartis can license other experimental drugs from Abogen's RNA platform.
ABO2203 is an mRNA-encoded CD19xCD3 T-cell engager, designed to instruct the patient’s own cells to produce a bispecific molecule that targets B cells in autoimmune diseases.
How the mRNA T cell engager works
ABO2203 uses a lipid nanoparticle (LNP) to deliver mRNA that encodes a CD19xCD3 T cell engager. Instead of giving patients a lab-made protein, this method tells their own cells to make the therapy. The molecule binds to CD19 on B cells and CD3 on T cells. The aim is to wipe out B cells that drive autoimmune diseases like immune thrombocytopenia (ITP) and lupus. This could reset the immune system without the hassle of cell therapy manufacturing. Reuters and Abogen both point to lupus and rheumatoid arthritis as main targets for this approach.
Early clinical data is sparse but worth noting. A recent Cell paper described three patients with tough-to-treat secondary ITP who got ABO2203. All three showed fast, complete loss of peripheral B cells, ongoing bone marrow depletion, and lasting platelet recovery for six months. Side effects were mild (grade 1 or 2). No cytokine release syndrome appeared. But the sample size is tiny. More research is needed to prove safety and benefit. ABO2203 is now in an early Phase I trial. Up to 66 patients with hard-to-treat autoimmune diseases will be enrolled. The study will check safety, tolerability, pharmacokinetics, pharmacodynamics, and early signs of efficacy.
Strategic context and industry implications
Novartis is chasing outside innovation, especially from China, to build its pipeline. In September, Novartis licensed a preclinical radioligand therapy from BoomRay Pharmaceuticals. That deal could reach $900 million. Novartis also works with Argo Biopharma on siRNA-based heart drugs. The pattern is clear. Global pharma is looking to Chinese biotech for new assets. Chinese firms keep domestic rights and find global partners for development and sales. This echoes other big deals, like the Zymeworks-Theravance transaction reported earlier.
For Novartis, the Abogen deal is more than just another asset. It is a bet on mRNA and LNP technology beyond vaccines. Manufacturing is shifting toward nucleic-acid drugs and advanced delivery. Novartis wants to compete in B cell depletion for autoimmune disease. CAR-T therapies have shown promise but are hard to make. If ABO2203 and similar programs succeed, Novartis could change how autoimmune diseases are treated. The road ahead is long. Results are not guaranteed.
Independent analysis by BioPharma Dive notes that ABO2203 was already in early clinical development at the time of the deal, which contributed to Novartis’s strong interest in Abogen’s RNA platform.
Novartis is not just buying a drug candidate. It is betting big on the future of mRNA in autoimmunity. The company is willing to spend billions even with early-stage data. That is a bold move. The next steps depend on clinical results and whether this science can help real patients.
